Psychovegetative syndrome: challenges in diagnosis and effective treatment
https://doi.org/10.21518/2079-701X-2018-21-50-55
Abstract
Autonomic dysfunction syndrome (ADS) includes the somatic (autonomic) function disorders of various origin and manifestations caused by their neurogenic regulation disorder. When establishing the diagnosis of ADS, the doctor most often implies psychovegetative syndrome (PVS), which is discussed in this article. Despite the fact that the ADS is not an independent nosological unit, most doctors use this term to provide the syndromic description of psychogenic polysystemic autonomic disorders. The ADS is mostly caused by mental disturbances of anxiety or anxiety-depressive nature within the neurotic, stress-related disorders, less often by an endogenous disease. The article describes the features of the ADS clinic picture, and focuses on hyperventilation syndrome. It discusses a clinical case of a patient with ADS (with florid hyperventilation syndrome), who was treated ineffectively with antidepressants. The authors also describe options for treating patients with ADS using a neuroleptic agent ziprasidone.
About the Authors
О. V. Kotova
Federal State Autonomous Educational Institution of Higher Education «Sechenov First Moscow State Medical University» of Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Kotova Olga Vladimirovna – Cand. of Sci. (Med.), neurologist, Federal State Autonomous Educational Institution of Higher Education «Sechenov First Moscow State Medical University» of Ministry of Health of the Russian Federation (Sechenov University), Vice-President of International Society «Stress under control»
8, Bldg. 2, Trubetskaya Str., Moscow, 119991
E. S. Akarachkova
Federal State Autonomous Educational Institution of Higher Education «Sechenov First Moscow State Medical University» of Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Akarachkova Elena Sergeevna – Dr. of Sci. (Med.), neurologist, Federal State Autonomous Educational Institution of Higher Education «Sechenov First Moscow State Medical University» of Ministry of Health of the Russian Federation (Sechenov University), President of the International Society «Stress under control»
8, Bldg. 2, Trubetskaya Str., Moscow, 119991
A. A. Belyaev
State Budgetary Healthcare Institution of Moscow «Sklifosovsky Research Institute of Emergency Medicine of the Department of Health of Moscow»
Russian Federation
Russian Federation
Belyaev Anton Andreevich – Junior Researcher of the Department of Emergency Vascular Surgery
3, Bldg. 21, B. Sukharevskaya Pl., Moscow, 129090
References
1. Wayne A.M., et al. Vegetative disorders: clinic, diagnosis, treatment. M.: MIA, 1998. 752 p. (In Russ).
2. Kotova O.V. Options for treatment of psycho-vegetative syndrome. Trudny Patsient. 2011; 12 (9): 24-27. (In Russ).
3. Wayne A.M., et al. Neurology for general practitioners. Eidos Media, 2001. 504 p. (In Russ).
4. Akarachkova E.S., Kotova O.V., Vershinina S.V., Ryabokon I.V. Stress and adjustment disorders. Lechaschy Vrach. 2014; 6: 61-65. (In Russ).
5. Akarachkova E.S. Revisiting the diagnosis and treatment of psycho-vegetative disorders in general practice. Lechaschy Vrach. 2010; 10: 5-8. (In Russ).
6. Toropina G.M. Cardialgia in the psycho-vegetative syndrome profile: extended abstract of Cand. of Sci. (Med.) Dissertation. M., 1992. 24 p. (In Russ).
7. Vorobieva O.V., Akarachkova E.S. Phytopreparations in the prevention and treatment of psycho-vegetative disorders. Vrach. Spetsialny Vypusk, 2007: 57-58. (In Russ).
8. Wayne A.M., Moldovanu I.V. Neurogenic hyperventilation. Chisinau: Shtiintsa, 1988, 184 p. (In Russ).
9. Wayne A.M., Solovyova A.D., Akarachkova ES. Magne-B6 therapy of hyperventilation syndrome. Lechenie Nervnykh Bolezney. 2003; 4, 3(11): 20-22. (In Russ).
10. Oganov R.G., Olbinskaya L.I., Smulevich A.B., et al. Depression and depressive spectrum disorders in general medical practice. Results of COMPASS program. Kardiologia. 2004; 1: 48-54. (In Russ).
11. Kotova O.V., Maksimova L.N. Patient with psycho-vegetative syndrome: general practitioner helping. Pharmateca. 2012; 19 (252): 36-41. (In Russ).
12. Kotova O.V., Belyaev A.A. The perspective of a neurologist on the premenstrual syndrome. Pharmateca. 2011; 9: 50-54. (In Russ).
13. Kozyrev V.N. Organization of psychiatric care for patients with mental disorders in the institutions of the medical network (principles and models of integrative medicine). M., 2000. (In Russ).
14. Avedisova A.S.. Anxiety disorders. In the book: Mental disorders in general medical practice and treatment. Alexandrovsky YuA. M.: GEOTAR-MED, 2004: 66-73. (In Russ).
15. Moroz S.M. The use of small neuroleptics in the clinic of internal diseases. Suchasna Gastroenterologia. 2007; 5 (37): 71–73. (In Russ).
16. Plotnikova E.Yu., Seledtsov A.M., Shamray M.A., Talitskaya E.A., Borsch M.V., Krasnov O.A. Psychosomatic aspects in gastroenterology. Lechaschy Vrach. 2012; 10: 96-99. (In Russ).
17. Mestre T.A., Zurowski M., Fox S.H. 5BHydroxytryptamine 2A receptor antagonists as potenB tial treatment for psychiatric disorders. Expert Opin Investig Drugs. 2013; 22(4): 411–421.
18. Morozov P.V. Zeldox (ziprasidone): a novel atypical neuroleptic agent. Psikhiatria i Psikhofarmakoterapia. 2005; 7 (5): 264-268. (In Russ).
19. Labbate L.A., Ayd F.J. Ziprasidone: The Latest FDA-Approved Atypical Antipsychotic. International Drug Therapy Newsletter. 2001 April; 36(4): 25–32.
20. Nemeroff C.B. et al. From clinical research to clinical practice: a 4Byear review of ziprasiB done. CNS Spectr. 2005; 10, 11(Suppl 17): 1–20.
21. Daniel D.G., Zimbroff D.L., Potkin D.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M. and the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbatieon of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychophsrmacolohy. 1999; 20: 491–505.
22. Park S.W. et al. Differential effects of ziprasidone and haloperidol on immobilization stressB induced mRNA BDNF expression in the hippocampus and neocortex of rats. J Psychiatr Res. 2009; 43(3): 274–281.
23. Kaengkan P. et al. Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats. Mol Cells. 2013; 36(6): 534–541.
24. Benninghoff J. et al. Ziprasidone – Not Haloperidol – Induces more deBnovo Neurogenesis of Adult Neural Stem Cells Derived from Murine Hippocampus. Pharmacopsychiatry. 2012; 46(1): 10–15.
25. Ushkalova E.A., Ushkalova A.V. Ziprasidone is a highly effective atypical neuroleptic agent with an improved safety profile. Pharmateca. 2005; 17: 10-19. (In Russ).
Review
For citations:
Kotova ОV, Akarachkova ES, Belyaev AA. Psychovegetative syndrome: challenges in diagnosis and effective treatment. Meditsinskiy sovet = Medical Council. 2018;(21):50-55. (In Russ.) https://doi.org/10.21518/2079-701X-2018-21-50-55
Views:
7996
Email this article 